Soliman MES - Search Results

1

Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives.

Washah HN, Salifu EY, Soremekun O, Elrashedy AA, Munsamy G, Olotu FA, Soliman MES. Washah HN, et al. Among authors: soliman mes. Comb Chem High Throughput Screen. 2020;23(8):687-698. doi: 10.2174/1386207323666200427113734. Comb Chem High Throughput Screen. 2020. PMID: 32338212 Review.

2

G-Protein Coupled Receptors (GPCRs): A Comprehensive Computational Perspective.

Ramesh M, Soliman ME. Ramesh M, et al. Comb Chem High Throughput Screen. 2015;18(4):346-64. doi: 10.2174/1386207318666150305155545. Comb Chem High Throughput Screen. 2015. PMID: 25747435 Review.

3

In silico identification of irreversible cathepsin B inhibitors as anti- cancer agents: virtual screening, covalent docking analysis and molecular dynamics simulations.

Sbongile M, Soliman ME. Sbongile M, et al. Comb Chem High Throughput Screen. 2015;18(4):399-410. doi: 10.2174/1386207318666150305154621. Comb Chem High Throughput Screen. 2015. PMID: 25747438

4

Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.

Ramesh M, Dokurugu YM, Thompson MD, Soliman ME. Ramesh M, et al. Comb Chem High Throughput Screen. 2017;20(6):492-509. doi: 10.2174/1386207320666170310121337. Comb Chem High Throughput Screen. 2017. PMID: 28294055 Review.

5

Dynamics of allosteric modulation of lymphocyte function associated antigen-1 closure-open switch: unveiling the structural mechanisms associated with outside-in signaling activation.

Abdullahi M, Olotu FA, Soliman ME. Abdullahi M, et al. Biotechnol Lett. 2017 Dec;39(12):1843-1851. doi: 10.1007/s10529-017-2432-0. Epub 2017 Sep 16. Biotechnol Lett. 2017. PMID: 28918491

6

Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.

El-Sayed S, Metwally K, El-Shanawani AA, Abdel-Aziz LM, El-Rashedy AA, Soliman MES, Quattrini L, Coviello V, la Motta C. El-Sayed S, et al. Among authors: soliman mes. Bioorg Med Chem Lett. 2017 Oct 15;27(20):4760-4764. doi: 10.1016/j.bmcl.2017.08.050. Epub 2017 Aug 24. Bioorg Med Chem Lett. 2017. PMID: 28935265

7

From mutational inactivation to aberrant gain-of-function: Unraveling the structural basis of mutant p53 oncogenic transition.

Olotu FA, Soliman MES. Olotu FA, et al. Among authors: soliman mes. J Cell Biochem. 2018 Mar;119(3):2646-2652. doi: 10.1002/jcb.26430. Epub 2017 Dec 12. J Cell Biochem. 2018. PMID: 29058783

8

Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors.

Metwally K, Pratsinis H, Kletsas D, Quattrini L, Coviello V, Motta C, El-Rashedy AA, Soliman ME. Metwally K, et al. Future Med Chem. 2017 Dec;9(18):2147-2166. doi: 10.4155/fmc-2017-0149. Epub 2017 Nov 3. Future Med Chem. 2017. PMID: 29098865

9

Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.

El Rashedy AA, Olotu FA, Soliman MES. El Rashedy AA, et al. Among authors: soliman mes. Chem Biodivers. 2018 Mar;15(3):e1700533. doi: 10.1002/cbdv.201700533. Epub 2018 Mar 7. Chem Biodivers. 2018. PMID: 29325229

10

Allosteric inhibition abrogates dysregulated LFA-1 activation: Structural insight into mechanisms of diminished immunologic disease.

Abdullahi M, Olotu FA, Soliman ME. Abdullahi M, et al. Comput Biol Chem. 2018 Apr;73:49-56. doi: 10.1016/j.compbiolchem.2018.02.002. Epub 2018 Feb 5. Comput Biol Chem. 2018. PMID: 29427909

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

283 results

Search Page

Filters